Leuven, Belgium, 26 April 2019 -Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease,announced today two podium presentations and a poster presentation atthe Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held April 28 - May 2, 2019 in Vancouver at the Vancouver Convention Centre.

The podium presentation 'The effect of combined PlGF and VEGF inhibition on vascular leakage and inflammation in experimental murine models' will be delivered Sunday, April 28 at 3.45 - 4.00 p.m. PDT.

The poster 'Placental growth factor (PlGF) induced signalling regulates barrier properties of the retinal pigment epithelium (RPE)' will be presented Monday, April 29 at 11.15 a.m. - 1.00 p.m. PDT.

The podium presentation 'A potential role for Src during early experimental diabetic retinopathy?' will be delivered on Tuesday, April 30 at 8.45 - 9.00 a.m. PDT.

Attachments

  • Original document
  • Permalink

Disclaimer

Oxurion NV published this content on 26 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 April 2019 05:27:12 UTC